ArticleJournal of the American Society of Nephrology : JASN2009
Plasma ADMA predicts restenosis of arteriovenous fistula.
Article in Journal of the American Society of Nephrology : JASN, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Factors influencing patency after percutaneous transluminal angioplasty for autogenous arteriovenous fistulae: a systematic review and meta-analysis.Renal failure · 2026Pooled it
- A Systematic Review and Meta-Analysis of Circulating Biomarkers Associated with Failure of Arteriovenous Fistulae for Haemodialysis.PloS one · 2016Pooled it
- Incidence and Predictors of Acute Coronary Syndrome in Patients on Maintenance Hemodialysis: A Prospective Cohort Study.Acta Cardiologica Sinica · 2024Article
- Far-Infrared Therapy Improves Arteriovenous Fistula Patency and Decreases Plasma Asymmetric Dimethylarginine in Patients with Advanced Diabetic Kidney Disease: A Prospective Randomized Controlled Trial.Journal of clinical medicine · 2022Article
- The association of long-term blood pressure variability with hemodialysis access thrombosis.Frontiers in cardiovascular medicine · 2022Article
- The Role of Oxidative Stress Markers in Predicting Acute Thrombotic Occlusion of Haemodialysis Vascular Access and Progressive Stenotic Dysfunction Demanding Angioplasty.Antioxidants (Basel, Switzerland) · 2021Article
- Predictors associated with early and late restenosis of arteriovenous fistulas and grafts after percutaneous transluminal angiography.Annals of translational medicine · 2021Article
- Factors associated with outcome after successful radiological intervention in arteriovenous fistulas: A retrospective cohort.The journal of vascular access · 2019Article
- Temporal distribution and biological determinants of thrombotic events after interventions for dialysis vascular access.Scientific reports · 2019Article
- Deterioration of Deceleration Capacity of Heart Rate is Associated with Left Ventricular Hypertrophy in End-Stage Renal Disease Population.Acta Cardiologica Sinica · 2018Article
- Asymmetric Dimethylarginine does not Predict Early Access Events in Hemodialysis Patients with Brachiocephalic Fistula Access.International journal of nephrology and kidney failure · 2017Article
- Future research directions to improve fistula maturation and reduce access failure.Seminars in vascular surgery · 2016Review
- Predicting the Functionality and Form of a Dialysis Fistula.Journal of the American Society of Nephrology : JASN · 2016Article
- Dialysis Vascular Access Intervention and the Search for Biomarkers.Journal of the American Society of Nephrology : JASN · 2016Article
- Morphometric and histological parameters in veins of diabetic patients undergoing brachiocephalic fistula placement.Hemodialysis international. International Symposium on Home Hemodialysis · 2015Article
- Hemodynamic and biologic determinates of arteriovenous fistula outcomes in renal failure patients.BioMed research international · 2015Review
- The impact of endothelial progenitor cells on restenosis after percutaneous angioplasty of hemodialysis vascular access.PloS one · 2014Article
- Novel paradigms for dialysis vascular access: downstream vascular biology--is there a final common pathway?Clinical journal of the American Society of Nephrology : CJASN · 2013Review
- Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia.Toxicological sciences : an official journal of the Society of Toxicology · 2010Article
- Characterization of a model of an arteriovenous fistula in the rat: the effect of L-NAME.The American journal of pathology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma levels of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide production, correlate with endothelial dysfunction and the development of cardiovascular events in patients with uremia. It is not known whether endothelial dysfunction contributes to the dysfunction of arteriovenous fistulas (AVFs) in hemodialysis patients. Here, we studied the predictive value of baseline plasma ADMA for symptomatic restenosis of an AVF after percutaneous transluminal angioplasty in dialysis patients. We obtained baseline plasma ADMA levels before percutaneous transluminal angioplasty in 100 consecutive patients with dysfunctional AVFs. Patients were followed up clinically for up to 6 mo after angioplasty for recurrent dysfunction. During the 6 mo after angioplasty, 46 patients experienced recurrent dysfunction of their AVF; of these, follow-up fistulography showed restenosis at the same location in 41, new stenosis at different locations in two, and no significant stenosis in three patients. Up to 60% of the patients with high levels of ADMA (>0.910 microM) had target lesion restenosis compared with 25% of those with low levels (<0.910 microM; P < 0.001). In multivariate analysis, plasma ADMA independently nearly tripled the risk for recurrent symptomatic stenosis of an AVF after percutaneous transluminal angioplasty (hazard ratio 2.65; 95% confidence interval 1.33 to 5.28). These results suggest a role for ADMA in the progression of symptomatic restenoses of AVFs after percutaneous transluminal angioplasty and call for preventive strategies that target ADMA and/or endothelial dysfunction to decrease the risk for AVF restenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.